MBF Bioscience

MBF Bioscience develops advanced microscopy hardware and image analysis software that have become gold standards in neuroscience and broader biosciences. Their flagship product Neurolucida has over two decades of continuous development and more than six thousand citations. The company’s technologies have been referenced in nearly twenty thousand peer-reviewed publications across diverse fields including brain mapping, cancer biology, stem cell research, toxicology studies and more.[5][2][3]

They do not conduct clinical trials or develop drugs but enable scientific discovery through their imaging solutions.

Recent growth includes the acquisition of Vidrio Technologies for two-photon imaging solutions in 2021 and Neurophotometrics LLC for fiber photometry equipment in 2023.[2][5]

Recognized by NIH/NIMH as a key innovator supported by SBIR/STTR programs; recipient of the Tibbetts Award from the U.S. Small Business Administration.[5]

Collaborates with leading academic institutions on new imaging technologies such as ClearScope with Columbia University.

Offices span North America (Vermont HQ), Europe (Netherlands), Asia (South Korea/Japan).[1][2][4]

No drug pipeline or clinical programs.